2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1381

The ZC3HC1 rs11556924 Polymorphism Is Associated With Increased Carotid Intima-Media Thickness In Patients With Rheumatoid Arthritis
Abstract Number: 2655

Therapeutic Effect Of β2GPI and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation
Abstract Number: 555

Therapeutic Inhibition Of Anti-Apoptotic BCL-2 Family Proteins In a Murine Model Of Lupus Nephritis
Abstract Number: 1469

Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1^st Anti-TNF: Results of the Multicenter Randomized Controlled “ROC” Trial
Abstract Number: 208

Three Approaches To Evaluating Step Therapy Policies For Immune Disorder Specialty Pharmaceuticals
Abstract Number: 2185

Three Middle Finger Width Correlates With Maximum Mouth Opening and Is a New Reliable Parameter To Identify Joint Hypermobility In Schoolchildren
Abstract Number: 1837

Three-Dimension Culture Of Mesenchymal Stem Cells With Nano-Fiber Scaffold Induces Chondrogenesis and Osteogenesis
Abstract Number: 1442

Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
Abstract Number: 2255

Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Abstract Number: 80

Tidemark Duplication In Osteoarthritis: Evidence Of Incremental Progression?
Abstract Number: 353

Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets
Abstract Number: 1338

Time To Institution Of Disease Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Abstract Number: 881

Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Abstract Number: 2126

Time Trends In Total Ankle Arthroplasty: A Study Of The U.S. National Inpatient Sample
Abstract Number: 2598

Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].